Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of...
46 insider purchases on record · latest filing 2026-09-21.
Insiders have also filed 40 sale transactions at BOLT.